Category: Pharma, Life Sciences & Med Tech Players
-
BREAKING: GSK cashes in on license deal as CureVac settles U.S. patent dispute with acquirer BioNTech and Pfizer for $790M+
Pfizer and BioNTech have settled their three-year COVID vaccine-related patent infringement dispute with CureVac in the U.S., granting the latter and its licensing partner GSK $370 million each.
-
An interview with Bayer’s outgoing head of IP Dr. Jörg Thomaier, new head Dorian Immler
Following three decades at Bayer, Dr. Jörg Thomaier is retiring as head of IP, super confident that his replacement Dorian Immler will have the energy and drive to make the changes that the department needs to keep prospering.
-
UK wrongful-enforcement damages standard at issue in Sandoz v. Bayer; disclosures in South African patent lawsuits can influence parallel cases
Sandoz is seeking a disgorgement of profits from Bayer, alleging that misrepresentations to the European Patent Office are a basis for going beyond the usual compensation.